Document is current
Any future updates will be listed below
-
Authors
Klimchak, Alexa C. https://orcid.org/0000-0001-8196-7093
Signorovitch, James https://orcid.org/0000-0002-4067-8962
Innis, Bryan https://orcid.org/0009-0008-7274-3942
Laverty, Chamindra G. https://orcid.org/0000-0001-5676-7516
Gooch, Katherine https://orcid.org/0009-0000-6382-614X
-
Funding
Funding for this research was provided by:
Sarepta Therapeutics, Inc.
- License Information
-
More Information
Article History
Received: 28 August 2024
Accepted: 17 October 2024
First Online: 11 November 2024
Declarations
:
: James Signorovitch is an employee of Analysis Group, Inc., which has received consulting fees from Sarepta Therapeutics, Inc. Alexa C. Klimchak, Bryan Innis, and Katherine Gooch are employees of Sarepta Therapeutics, Inc., and may own stock/options in the company. Chamindra G Laverty declares contracts (as principal investigator) from Sarepta Therapeutics, Dyne Therapeutics, Avidity Biosciences, FibroGen, Scholar Rock, Novartis Gene Therapies, and Biohaven; consulting fees from Sarepta Therapeutics (payments to her institution), NS Pharma (payments to herself), and Avidity (payments to her institution), Catalyst (payments to herself), SolidBio (payments to herself), Novartis (payments to herself), Biogen (payments to herself); and support for attending meetings and/or travel from the Muscular Dystrophy Association, CureCMD, and CureSMA.
: MarketScan® data included in this study were provided by and used with permission from Merative™. Institutional review board approval was not required to conduct this study, as data were de-identified and compliant with Health Insurance Portability and Accountability Act (HIPAA) regulations.
